Accession Number : ADA302243

Title :   Oral Adjuvant Therapy in the Development of Immunological Protection Against Mucosal Pathogens.

Descriptive Note : Final rept. Aug 92-Jul 95,

Corporate Author : TULANE UNIV NEW ORLEANS LA SCHOOL OF MEDICINE

Personal Author(s) : Clements, John D.

PDF Url : ADA302243

Report Date : JUL 1995

Pagination or Media Count : 5

Abstract : Here we report the development of a non-toxic adjuvant for orally administered antigens that can elicit the production of both serum IgG and mucosal IgA against antigens with which it is delivered. This adjuvant is a mutant form of the heat-labile cholera-like toxin of E. coli. This adjuvant, designated L/T(Rl92G), acts as a mucosal adjuvant, increasing the serum IgG and mucosal IgA responses to co-administered antigen beyond that achieved with administration of antigen alone. Further, L/T(Rl92G) prevented the induction of tolerance to antigen and did not induce tolerance against itself as demonstrated by the presence of significant serum anti-LT IgG and mucosal anti-LT IgA antibodies in immunized mice. In addition to its potential use as an adjuvant for unrelated antigens, use of this non-toxic adjuvant as one component of a whole-cell/toxoid vaccine against cholera-related enteropathies should provide more epitopes for induction of neutralizing antibodies as well as adjuvant activity not associated with B subunit alone. In addition, this mutant LT provides for the first time a model system in which to examine the role of proteolytic processing with respect to the enterotoxic and immunologic properties of ADP-ribosylating toxins both in vitro and in vivo.

Descriptors :   *ANTIBODIES, *ANTIGENS, *PATHOGENIC MICROORGANISMS, *MUCOUS MEMBRANES, PRODUCTION, MODELS, NEUTRALIZATION, PROTECTION, THERAPY, MICE, IMMUNOLOGY, IN VIVO ANALYSIS, INDUCTION SYSTEMS.

Subject Categories : Anatomy and Physiology
      Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE